Technology appraisal committee meeting (committee B)

15 July 2026

Zoom

Draft Agenda

 The meeting will take place via Zoom, a secure web conferencing tool.

The meeting will run from 9:00am to 5:45pm, although this may be subject to change.  Joining links and times for each topic and further instructions will be sent 1-2 days before the meeting.

Please note that this agenda is a draft and is suject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
    3.1. Minutes from the last committee meeting held on 17 June 2026 – Part 1 only (open session)
  4. Appraisal of nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]
    • 4.1. Intoduction by the Chair, Dr Charles Crawley – Part 1 only (open session)
    • 4.2. Declaration of interests – Part 1 only (open session)
    • 4.3. Presentation by the lead team Kemi Gibson, Tony Wootton and Vanessa Danielson – Part 1 AND part 2 (open and closed session)
    • 4.4. Agreement on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)
  5. Appraisal of tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]
    • 5.1. Intoduction by the Chair, Dr Charles Crawley – Part 1 only (open session)
    • 5.2. Declaration of interests – Part 1 only (open session)
    • 5.3. Presentation by the Chair, Dr Charles Crawley – Part 1 AND part 2 (open and closed session)
    • 5.4. Agreement on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)
  6. Appraisal of nirogacestat for treating desmoid tumours [ID6453]
  • 6.1. Intoduction by the Vice-Chair, Baljit Singh – Part 1 only (open session)
  • 6.2. Declaration of interests – Part 1 only (open session)
  • 6.3. Presentation by the Vice-Chair, Baljit Singh – Part 1 AND part 2 (open and closed session)
  • 6.4. Agreement on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Important information on how to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to observe.
  • Once registration has closed, you will receive your unique joining link for the meeting.
  • Registration will close on Monday 9 July 2026
  • When registration closes you will receive a confirmation email whether you have been allocated a place or not. You must let us know if you intend to keep this place at least 5 working days before the meeting.
  • We will add your registration details to the virtual web conferencing tool (Zoom) and joining instructions will be sent about 1-2 days before the meeting.
  • We will not be able to accept any late requests or name changes after we have registered attendees for the virtual Zoom meeting.

    Privacy statement - We use Zoom to host our web meetings. When you join a zoom web meeting, your name, email and IP address will be processed. We ask for this data to help facilitate the event and monitor attendance. If the web meeting you are attending offers an interactive poll or Q&A session, participation is not mandatory, however your name may be processed with your poll responses and questions. We store this information in Zoom for 6 months. Further information about how we manage personal data at NICE can be found on our privacy notice – https://www.nice.org.uk/privacy-notice

  • Should you have any queries regarding observing this meeting, please contact the Coordinator.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document

REGISTRATION IS NOW OPEN: 

TOPIC 1: nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

TOPIC 2: tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

TOPIC 3: nirogacestat for treating desmoid tumours [ID6453]

As you have registered directly on Zoom, please make sure you note the meeting date and time in your diary. You will receive confirmation with your joining link and further information once registration has closed.

Date and time of next meeting

The next meeting will take place on Wednesday 13 August 2026 at 9.00am, via Zoom.

Please note all timings are approximate